GGrantIndex
← Leaderboards

Abbot Frederick Clark

University Of North Texas Hlth Sci Ctr

Google Scholar ↗PubMed ↗ORCID ↗
$5,334,701
Attributed
$11,337,651
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY2010–25
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,337,651 · 7

By mechanism

R01$10,216,526 · 4
R21$1,121,125 · 3

Top collaborators

Most similar at University Of North Texas Hlth Sci Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Physiologic Intraocular Pressure”

  • Rohit Varma · University Of Southern California$30,984,208
  • David Huang · Cleveland Clinic Lerner Col/Med-Cwru$13,270,313
  • Ted S Acott · Oregon Health And Science University$13,179,038
  • Simon W John · Columbia University Health Sciences$12,170,988
  • Keri Hammel · The Emmes Company, Llc$11,951,805
  • Keri, Hammel · The Emmes Company, Llc$11,064,901

Research focus

Physiologic Intraocular PressureGlaucomaTrabecular Meshwork StructureBlindnessAqueous HumorPrimary Open Angle GlaucomaRisk FactorsAnteriorCellsOcular HypertensionMouse ModelPathway InteractionsMolecularIn VivoPerfusionTissuesResistanceGene TherapyMyocilinGenesChronicKnock-DownGlucocorticoidsPlay

Grant awards (29)

Discovery of novel disease modifying therapy for the prevention and treatment of glaucoma$222,000
R21 · FY2025 · EY · contact PI
Glucocorticoids, ocular hypertension and glaucoma$557,079
R01 · FY2024 · EY · contact PI
Discovery of novel disease modifying therapy for the prevention and treatment of glaucoma$185,000
R21 · FY2024 · EY · contact PI
Glucocorticoids, ocular hypertension and glaucoma$557,079
R01 · FY2023 · EY · contact PI
Novel Genome Editing for the Treatment of Glaucoma$473,396
R01 · FY2023 · EY
Administrative Supplement for Research on Vitamin B3 Dietary Supplements for Eye Disease$149,340
R01 · FY2023 · EY
Glucocorticoids, ocular hypertension and glaucoma$540,367
R01 · FY2022 · EY · contact PI
Novel Genome Editing for the Treatment of Glaucoma$459,195
R01 · FY2022 · EY
Glucocorticoids, ocular hypertension and glaucoma$540,366
R01 · FY2021 · EY · contact PI
Novel Genome Editing for the Treatment of Glaucoma$527,925
R01 · FY2021 · EY
Glucocorticoids, ocular hypertension and glaucoma$558,974
R01 · FY2020 · EY · contact PI
Novel Genome Editing for the Treatment of Glaucoma$477,939
R01 · FY2020 · EY
Novel Genome Editing for the Treatment of Glaucoma$70,857
R01 · FY2020 · EY
Novel Genome Editing for the Treatment of Glaucoma$491,564
R01 · FY2019 · EY
Novel Glaucoma Treatment Using Genome Editing$508,361
R01 · FY2018 · EY
Glucocorticoids, Ocular Hypertension, and Glaucoma$365,000
R01 · FY2018 · EY · contact PI
Novel Glaucoma Treatment Using Genome Editing$508,361
R01 · FY2017 · EY
Novel Glaucoma Treatment Using Genome Editing$508,361
R01 · FY2016 · EY
Glucocorticoids, ocular hypertension, and glaucoma$376,688
R01 · FY2016 · EY · contact PI
Novel Glaucoma Treatment Using Genome Editing$508,558
R01 · FY2015 · EY
Glucocorticoids, ocular hypertension, and glaucoma$369,153
R01 · FY2015 · EY · contact PI
Conditionally immortalized TM cell and RGC lines from Animal Model$177,625
R21 · FY2015 · EY · contact PI
Novel Glaucoma Treatment Using Genome Editing$558,268
R01 · FY2014 · EY
Glucocorticoids, ocular hypertension, and glaucoma$369,154
R01 · FY2014 · EY · contact PI
Conditionally immortalized TM cell and RGC lines from Animal Model$145,000
R21 · FY2014 · EY · contact PI
Glucocorticoids, ocular hypertension, and glaucoma$357,853
R01 · FY2013 · EY · contact PI
Glucocorticoids, ocular hypertension, and glaucoma$382,688
R01 · FY2012 · EY · contact PI
A New Model of Human Primary Open-Angle Glaucoma$174,000
R21 · FY2011 · EY · contact PI
A New Model of Human Primary Open-Angle Glaucoma$217,500
R21 · FY2010 · EY · contact PI